Evidence map›Paper›PMID 32283266›Full record

Observational studyClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2021

Characteristics of human metapneumovirus infection in adults hospitalized for community-acquired influenza-like illness in France, 2012-2018: a retrospective observational study.

P Loubet, P Mathieu, N Lenzi, F Galtier, F Lainé, Z Lesieur, P Vanhems, X Duval, D Postil, S Amour and 9 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02027233 (Efficiency in Population of Influenza Vaccination for Flu Prevention of the Hospitalized Adults), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02027233 nacompletednot on this map

Efficiency in Population of Influenza Vaccination for Flu Prevention of the Hospitalized Adults

TypeinterventionalSponsorInstitut National de la Santé Et de la Recherche Médicale, FranceRan2014 to 2022Enrolled6,173ConditionsSevere Acute Respiratory InfectionArmsnasopharyngeal sample
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. The risk of cardiac disease events after respiratory syncytial virus disease: a systematic literature review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  2. Twenty-five years of human metapneumovirus research.Clinical microbiology reviews · 2026
    Review
  3. Article
  4. Article
  5. Awareness of human metapneumovirus (hMPV) among healthcare professionals in Libya.The Journal of the Egyptian Public Health Association · 2026
    Article
  6. Article
  7. Burden of Human Metapneumovirus in India: Epidemiological Trends and Clinical Impact.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 2 countries.

P LoubetVBMI, INSERM U1047, Department of Infectious and Tropical Disease, CHU Nîmes, Univ Montpellier, Nîmes, France; Inserm, F-CRIN, Réseau Innovative Clinical Research in Vaccinology (I-REIVAC), Paris, France. Electronic address: paul.loubet@chu-nimes.fr.
P MathieuUniversité Paris Descartes, Sorbonne Paris Cité, Inserm, CIC Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
N LenziInserm, F-CRIN, Réseau Innovative Clinical Research in Vaccinology (I-REIVAC), Paris, France.
F GaltierInserm, F-CRIN, Réseau Innovative Clinical Research in Vaccinology (I-REIVAC), Paris, France; CIC1411, CHU Montpellier, Hôpital Saint Eloi, Montpellier, F-34295, France.
F LainéInserm, F-CRIN, Réseau Innovative Clinical Research in Vaccinology (I-REIVAC), Paris, France; Centre d'Investigations Cliniques, INSERM UMR CIC 1414, Hôpital Pontchaillou, Rennes, France.
Z LesieurInserm, F-CRIN, Réseau Innovative Clinical Research in Vaccinology (I-REIVAC), Paris, France.
P VanhemsInserm, F-CRIN, Réseau Innovative Clinical Research in Vaccinology (I-REIVAC), Paris, France; Service d'Hygiène, Epidémiologie et Prévention, Hospices Civils de Lyon, F-69437 Lyon, France.
X DuvalInserm, F-CRIN, Réseau Innovative Clinical Research in Vaccinology (I-REIVAC), Paris, France; CIC1125, Hôpital Bichat Claude Bernard, Paris, France.
D PostilCHU Dupuytren, CIC 1435, Limoge Cedex, France.
S AmourService d'Hygiène, Epidémiologie et Prévention, Hospices Civils de Lyon, F-69437 Lyon, France.
S RogezCHU Dupuytren, Service Bactériologie, Virologie, Hygiène, Limoges Cedex, France.
G LagathuUniversité Rennes-I, Virologie, Hôpital Pontchaillou, Rennes, France.
A-S L'HonneurAHU, Service de Virologie, Hôpital Cochin, Paris, France.
V FoulongneService de Virologie, CHU Montpellier, Hôpital Saint Eloi, Montpellier, F-34295, France.
N HouhouLaboratoire de Virologie, Hôpital Bichat Claude Bernard, Paris, France.
B LinaHospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Centre National de Référence des virus Respiratoires France Sud, Hôpital de la Croix-Rousse, 69317 Lyon Cedex 04, France.
F CarratSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Saint Antoine, F75013 Paris, France.
O LaunayInserm, F-CRIN, Réseau Innovative Clinical Research in Vaccinology (I-REIVAC), Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Inserm, CIC Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
Fluvac study group
Inserm · FRDélégation Paris 5 · FRHôpital Dupuytren · FRUniversité Claude Bernard Lyon 1 · FRHôpital Cochin · FRHôpital de la Croix-Rousse · FRHôpital Pontchaillou · FRHôpital Saint Eloi · FRHospices Civils de Lyon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo describe the prevalence, clinical features and complications of human metapneumovirus (hMPV) infections in a population of adults hospitalized with influenza-like illness (ILI).

methodsThis was a retrospective, observational, multicenter cohort study using prospectively collected data from adult patients hospitalized during influenza virus circulation, for at least 24 h, for community-acquired ILI (with symptom onset <7 days). Data were collected from five French teaching hospitals over six consecutive winters (2012-2018). Respiratory viruses were identified by multiplex reverse transcription polymerase chain reaction (RT-PCR) on nasopharyngeal specimens. hMPV + patients were compared with hMPV- patients, influenza+ and respiratory syncytial virus (RSV)+ patients using multivariate logistic regressions. Primary outcome was the prevalence of hMPV in patients hospitalized for ILI.

resultsAmong the 3148 patients included (1449 (46%) women, 1988 (63%) aged 65 and over; 2508 (80%) with chronic disease), at least one respiratory virus was detected in 1604 (51%, 95% confidence interval (CI) 49-53), including 100 cases of hMPV (100/3148, 3% 95% CI 3-4), of which 10 (10%) were viral co-infection. In the hMPV + patients, mean length of stay was 7 days, 62% (56/90) developed a complication, 21% (14/68) were admitted to intensive care unit and 4% (4/90) died during hospitalization. In comparison with influenza + patients, hMPV + patients were more frequently >65 years old (adjusted odds ratio (aOR) = 3.3, 95% CI 1.9-6.3) and presented more acute heart failure during hospitalization (aOR = 1.8, 95% CI 1.0-2.9). Compared with RSV + patients, hMPV + patients had less cancer (aOR = 0.4, 95% CI 0.2-0.9) and were less likely to smoke (aOR = 0.5, 95% CI 0.2-0.9) but had similar outcomes, especially high rates of respiratory and cardiovascular complications.

conclusionsAdult hMPV infections mainly affect the elderly and patients with chronic conditions and are responsible for frequent cardiac and pulmonary complications similar to those of RSV infections. At-risk populations would benefit from the development of antivirals and vaccines targeting hMPV.

Indexed as

AgedAged, 80 and overCommunity-Acquired InfectionsFemaleFranceHospitalizationHumansInfluenza, HumanMaleMetapneumovirusMiddle AgedNasopharynxOrthomyxoviridaeParamyxoviridae InfectionsPrevalenceRespiratory Syncytial Virus, HumanAdultsHuman metapneumovirusInfluenzaInfluenza-like-illnessRespiratory syncytial virus

Identifiers

PMID32283266
PMCPMC7195031
OpenAlexW3015966792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.